CareTrust REIT (CTRE) is an Incredible Growth Stock: 3 Reasons Why

CareTrust REIT (CTRE) is identified by Zacks Investment Research as a strong growth stock, holding a Zacks Rank #2 and a Growth Score of B, indicating potential outperformance. This assessment is driven by robust financial projections, including an anticipated 20.9% EPS growth and 67.6% year-over-year cash flow growth, both significantly exceeding industry averages. Positive earnings estimate revisions, with current-year estimates up 0.5% in the past month, further underscore CTRE's appeal to growth investors.

Analysis

CareTrust REIT (CTRE) presents a compelling growth profile according to Zacks Investment Research, which has assigned the company a Zacks Rank #2 (Buy) and a Growth Score of B. The healthcare real estate investment trust's bullish outlook is primarily driven by its significant projected earnings growth of 20.9% for the current year, which starkly contrasts with the industry average forecast of just 0.8%. This forward momentum is further substantiated by exceptional cash flow metrics; CTRE's year-over-year cash flow growth stands at 67.6%, dwarfing the peer average of 2.7%. The company has also demonstrated a consistent ability to generate cash, with a 3-5 year annualized cash flow growth rate of 12.5% versus the industry's 3.1%. Reinforcing this positive fundamental picture, the stock has seen upward earnings estimate revisions, with the Zacks Consensus Estimate for the current year rising 0.5% in the past month, a factor often correlated with near-term price appreciation. The combination of these factors positions CTRE as a potential outperformer within its sector.

Key Decisions for Investors

• Given the strong buy signal from a proprietary ranking system and forward-looking metrics that significantly outpace industry averages, growth-oriented investors should consider CTRE for a long position.
• The investment thesis hinges on the company achieving its aggressive 20.9% EPS growth forecast; investors should monitor upcoming quarterly earnings reports closely for any signs of deviation from this projection.
• Since CTRE's cash flow growth of 67.6% is a key differentiator, it is prudent to track its operating cash flow in subsequent financial statements to ensure this high rate of capital accumulation is sustained to fund future projects.
• Investors should assess if CTRE's superior growth prospects relative to its peers are already reflected in its current valuation or if there remains potential for further multiple expansion.